ICYMI: Biogen, GSK And Roche Slip Pipeline Setbacks Into Earnings Reports
The first round of third-quarter earnings reports for big pharmas quietly featured news about drug discontinuations and failures.
You may also be interested in...
Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.
Roche's development plans for a follow-on Avastin product have been called into question after the company noted briefly in its third-quarter earnings update that the drug failed in a Phase II study in colorectal cancer patients.
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.